Voyager Therapeutics Inc (VYGR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Voyager Therapeutics Inc (VYGR) has a cash flow conversion efficiency ratio of -0.141x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.05 Million) by net assets ($219.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Voyager Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Voyager Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Voyager Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Voyager Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Voyager Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Amar Indonesia
JK:AMAR
|
0.022x |
|
Chicago Atlantic BDC, Inc.
NASDAQ:LIEN
|
0.000x |
|
Starpharma Holdings Ltd
AU:SPL
|
0.182x |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd B
SHG:900911
|
-0.111x |
|
Excelliance MOS
TWO:5299
|
0.024x |
|
Magni Tech Industries Bhd
KLSE:7087
|
0.069x |
|
PERPETUAL EQU. INV.
F:P82
|
N/A |
|
TERACT EO 1
F:6O8
|
N/A |
Annual Cash Flow Conversion Efficiency for Voyager Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Voyager Therapeutics Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see VYGR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $299.76 Million | $-15.31 Million | -0.051x | -115.49% |
| 2023-12-31 | $236.32 Million | $77.92 Million | 0.330x | +255.57% |
| 2022-12-31 | $59.02 Million | $-12.51 Million | -0.212x | +62.36% |
| 2021-12-31 | $95.06 Million | $-53.52 Million | -0.563x | +10.15% |
| 2020-12-31 | $154.32 Million | $-96.72 Million | -0.627x | -228.15% |
| 2019-12-31 | $99.51 Million | $48.67 Million | 0.489x | +242.97% |
| 2018-12-31 | $46.45 Million | $-15.89 Million | -0.342x | +25.26% |
| 2017-12-31 | $134.05 Million | $-61.35 Million | -0.458x | -46.43% |
| 2016-12-31 | $135.92 Million | $-42.48 Million | -0.313x | -227.95% |
| 2015-12-31 | $169.07 Million | $41.30 Million | 0.244x | +102.35% |
| 2014-12-31 | $1.15 Million | $-11.92 Million | -10.372x | -829.50% |
| 2013-12-31 | $-3.83 Million | $-5.45 Million | 1.422x | -- |
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more